Incretin ‐based glucose‐lowering medications and the risk for acute pancreatitis and/or pancreatic cancer risk: Reassuring data from cardio‐vascular outcome trials
Abstract
Incretin‐based medications (glucagon‐like peptide‐1 [GLP‐1] receptor agonists and inhibitors of dipeptidyl peptidase‐4 [DPP‐4] are glucose‐lowering drugs approved and introduced after 2006 (1). Although both classes of drugs appeared to be relatively safe based on results from clinical trials and standard animal toxicology studies, epidemiological data (2, 3) and histological findings (4) in genetically modified rodents exposed to such agents have raised concern that pancreatitis and pancreatic cancer may be long‐term risks associated with this therapy.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Michael A. Nauck, Juris J. Meier, Wolfgang E. Schmidt Tags: RESEARCH LETTER Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Clinical Trials | Diabetes | Eating Disorders & Weight Management | Endocrinology | Epidemiology | Genetics | Heart | Incretin Therapy | Obesity | Pancreas | Pancreatic Cancer | Pancreatitis | Study | Toxicology